Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katzenstein

Showing results (761-770 of 874) with videos related to

Pageof 88
Sort By:
Open Forum Infectious Diseases|July 16, 2016
Global Comparison of Drug Resistance Mutations After First-Line Antiretroviral Therapy Across Human Immunodeficiency Virus-1 SubtypesAustin Huang, Joseph W Hogan, Xi Luo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 29, 2015
Microbiota-Dependent Marker TMAO Is Elevated in Silent Ischemia but Is Not Associated With First-Time Myocardial Infarction in HIV InfectionJudith M Haissman, Andreas Knudsen, Hedda Hoel, et al.
Journal of the Neurological Sciences|June 18, 2025
Brain health trajectories 3 years after hospitalization for COVID-19, pneumonia, myocardial infarction, or critical illnessC Peinkhofer, C S Grønkjær, L E Bang, et al.
BMC Infectious Diseases|January 3, 2013
Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysisBarbara A Rath, Max von Kleist, Maria E Castillo, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|June 7, 2014
Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253C H Shiboski, H Chen, M A Ghannoum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2013
A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumorsLia Gore, Tanya M Trippett, Howard M Katzenstein, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 22, 2025
Change in pulmonary pathogens three years after elexacaftor/tezacaftor/ivacaftor: an observational study in the Danish cystic fibrosis cohortMaria Pals Bendixen, Majbritt Jeppesen, Oihane Irazoki, et al.
Journal of Clinical Microbiology|November 1, 1996
Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratoriesB Yen-Lieberman, D Brambilla, B Jackson, et al.
Plos One|May 27, 2010
Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutationsAlberto Diaz de Leon, Jennifer T Cronkhite, Anna-Luise A Katzenstein, et al.
Journal of Virology|May 23, 2014
Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adultsEmily C Liang, Lindsay Sceats, Nicholas L Bayless, et al.
Pageof 88

Showing results (761-770 of 874) with videos related to

Sort By:
Pageof 88
Open Forum Infectious Diseases|July 16, 2016
Global Comparison of Drug Resistance Mutations After First-Line Antiretroviral Therapy Across Human Immunodeficiency Virus-1 SubtypesAustin Huang, Joseph W Hogan, Xi Luo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 29, 2015
Microbiota-Dependent Marker TMAO Is Elevated in Silent Ischemia but Is Not Associated With First-Time Myocardial Infarction in HIV InfectionJudith M Haissman, Andreas Knudsen, Hedda Hoel, et al.
Journal of the Neurological Sciences|June 18, 2025
Brain health trajectories 3 years after hospitalization for COVID-19, pneumonia, myocardial infarction, or critical illnessC Peinkhofer, C S Grønkjær, L E Bang, et al.
BMC Infectious Diseases|January 3, 2013
Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysisBarbara A Rath, Max von Kleist, Maria E Castillo, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|June 7, 2014
Role of oral candidiasis in TB and HIV co-infection: AIDS Clinical Trial Group Protocol A5253C H Shiboski, H Chen, M A Ghannoum, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2013
A multicenter, first-in-pediatrics, phase 1, pharmacokinetic and pharmacodynamic study of ridaforolimus in patients with refractory solid tumorsLia Gore, Tanya M Trippett, Howard M Katzenstein, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|August 22, 2025
Change in pulmonary pathogens three years after elexacaftor/tezacaftor/ivacaftor: an observational study in the Danish cystic fibrosis cohortMaria Pals Bendixen, Majbritt Jeppesen, Oihane Irazoki, et al.
Journal of Clinical Microbiology|November 1, 1996
Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratoriesB Yen-Lieberman, D Brambilla, B Jackson, et al.
Plos One|May 27, 2010
Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutationsAlberto Diaz de Leon, Jennifer T Cronkhite, Anna-Luise A Katzenstein, et al.
Journal of Virology|May 23, 2014
Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adultsEmily C Liang, Lindsay Sceats, Nicholas L Bayless, et al.
Pageof 88